<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href='static/style.xsl' type='text/xsl'?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T10:49:52Z</responseDate><request verb="GetRecord" identifier="oai:ecommons.cornell.edu:1813/120719" metadataPrefix="dim">https://ecommons.cornell.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:ecommons.cornell.edu:1813/120719</identifier><datestamp>2026-05-15T17:54:24Z</datestamp><setSpec>com_1813_35</setSpec><setSpec>col_1813_47</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author">Chong, Kellie</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="chair" lang="en_US">Jiang, Shaoyi</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember" lang="en_US">Yu, Qiuming</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2026-04-02T18:34:37Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2025-08</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Submission ID: 12586</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Publication ID: 32171329</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1813/120719</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="doi">https://doi.org/10.7298/6wyh-vj21</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="bibid">17422661</dim:field>
   <dim:field mdschema="dc" element="description" lang="en_US">83 pages</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Despite chemotherapy’s widespread application for cancer treatment, its targeted delivery to neoplastic tissue, especially those lipophilic in nature, remains a major challenge. Leukocyte-derived small extracellular vesicles (EVs) have emerged as promising drug carriers due to their intrinsic tumor-targeting abilities and immunological inertness. To enhance the stability and drug loading capabilities of EVs, we developed a virus-like vesicle (VLV) drug delivery system comprised of engineered leukocyte-derived EVs expressing activity-regulated cytoskeleton-associated protein (Arc/Arg3.1) capsids and its 5’ untranslated region RNA stabilizing sequence. Our objective was to assess the VLV drug delivery platform for the encapsulation and delivery of hydrophobic mitochondrial-targeting chemotherapeutic drugs to treat triple-negative breast cancer (TNBC). Comparing endogenous and ex vivo loading strategies, endogenously loaded VLVs showed enhanced drug encapsulation and sustained cytotoxicity against TNBC cells over wild-type EVs. We conclude that the current system holds significant potential for the delivery of hydrophobic drugs to treat resistant cancers.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="embargo">2027-09-09</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en</dim:field>
   <dim:field mdschema="dc" element="rights">Attribution 4.0 International</dim:field>
   <dim:field mdschema="dc" element="rights" qualifier="uri">https://creativecommons.org/licenses/by/4.0/</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Breast Cancer</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Chemotherapy</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Extracellular Vesicles</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Nanomedicine</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Targeted Drug Delivery</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Targeting Triple-Negative Breast Cancer Metabolism Via Engineered Virus-Like Vesicle-Mediated Drug Delivery</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">dissertation or thesis</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="discipline">Chemical Engineering</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="grantor">Cornell University</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="level">Master of Science</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="name">M.S., Chemical Engineering</dim:field>
   <dim:field mdschema="dcterms" element="license">https://hdl.handle.net/1813/59810.2</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="collection" authority="https://ecommons.cornell.edu/handle/1813/47" confidence="600">Cornell Theses and Dissertations</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="author">Chong, Kellie</dim:field>
   <dim:field mdschema="cris" element="virtualsource" qualifier="collection">5893a6ea-7af3-41d7-abc6-04bcd26ab5df</dim:field>
   <dim:field mdschema="others" element="access-status">embargo</dim:field>
   <dim:field mdschema="others" element="access-status">embargo</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="76b7cbab-5d6e-4694-84ab-a487249fa31c">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
	&lt;Language>en&lt;/Language>
   	&lt;Title>Targeting Triple-Negative Breast Cancer Metabolism Via Engineered Virus-Like Vesicle-Mediated Drug Delivery&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2025-08&lt;/PublicationDate>
   	&lt;DOI>https://doi.org/10.7298/6wyh-vj21&lt;/DOI>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Chong, Kellie&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;License>https://creativecommons.org/licenses/by/4.0/&lt;/License>
    &lt;Keyword>Breast Cancer&lt;/Keyword>
    &lt;Keyword>Chemotherapy&lt;/Keyword>
    &lt;Keyword>Extracellular Vesicles&lt;/Keyword>
    &lt;Keyword>Nanomedicine&lt;/Keyword>
    &lt;Keyword>Targeted Drug Delivery&lt;/Keyword>
   	&lt;Abstract>Despite chemotherapy’s widespread application for cancer treatment, its targeted delivery to neoplastic tissue, especially those lipophilic in nature, remains a major challenge. Leukocyte-derived small extracellular vesicles (EVs) have emerged as promising drug carriers due to their intrinsic tumor-targeting abilities and immunological inertness. To enhance the stability and drug loading capabilities of EVs, we developed a virus-like vesicle (VLV) drug delivery system comprised of engineered leukocyte-derived EVs expressing activity-regulated cytoskeleton-associated protein (Arc/Arg3.1) capsids and its 5’ untranslated region RNA stabilizing sequence. Our objective was to assess the VLV drug delivery platform for the encapsulation and delivery of hydrophobic mitochondrial-targeting chemotherapeutic drugs to treat triple-negative breast cancer (TNBC). Comparing endogenous and ex vivo loading strategies, endogenously loaded VLVs showed enhanced drug encapsulation and sustained cytotoxicity against TNBC cells over wild-type EVs. We conclude that the current system holds significant potential for the delivery of hydrophobic drugs to treat resistant cancers.&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>